The biopsy results often lead to a diagnosis of GVHD even in cases judged to be endoscopically normal. Among the gastric endoscopic findings, mucosal exfoliation, although rare, and redness, luster, and mucosal change are likely to be useful diagnostic predictors of upper GI GVHD. GVHD was frequently diagnosed in patients with endoscopically normal duodenum, suggesting that biopsies are important for definitive diagnosis. “
“Hepatits C virus (HCV) is an enveloped virus selleck inhibitor with positive-sense single-stranded RNA genome that causes both acute and persistent infections associated with chronic
hepatitis, cirrhosis and hepatocellular carcinoma, which needs fully functional human hepatocytes for its development. Due to the strict human tropism of HCV, only human and higher primates such as chimpanzees have been receptive to HCV infection and development, cognition
about pathophysiololgy and host immune responses of HCV infection is limited by lacking of simple laboratory models of infection for a long time. During the past decade, gene transfer approaches have been helpful to the understanding of the molecular basis of human disease. Transgenic cell lines, chimeric and transgenic animal models were developed and had been demonstrated their invaluable benefits. This review focuses on the existing HCV transgenic models and summarize the relative results about probable pathophysical changes induced by HCV proteins. “
“Sinusoidal
vasoconstriction, in which hepatic stellate cells operate as contractile machinery, www.selleckchem.com/products/FK-506-(Tacrolimus).html has been suggested learn more to play a pivotal role in the pathophysiology of portal hypertension. We investigated whether sphingosine 1-phosphate (S1P) stimulates contractility of those cells and enhances portal vein pressure in isolated perfused rat livers with Rho activation by way of S1P receptor 2 (S1P2). Rho and its effector, Rho kinase, reportedly contribute to the pathophysiology of portal hypertension. Thus, a potential effect of S1P2 antagonism on portal hypertension was examined. Intravenous infusion of the S1P2 antagonist, JTE-013, at 1 mg/kg body weight reduced portal vein pressure by 24% without affecting mean arterial pressure in cirrhotic rats induced by bile duct ligation at 4 weeks after the operation, whereas the same amount of S1P2 antagonist did not alter portal vein pressure and mean arterial pressure in control sham-operated rats. Rho kinase activity in the livers was enhanced in bile duct-ligated rats compared to sham-operated rats, and this enhanced Rho kinase activity in bile duct-ligated livers was reduced after infusion of the S1P2 antagonist. S1P2 messenger RNA (mRNA) expression, but not S1P1 or S1P3, was increased in bile duct-ligated livers of rats and mice and also in culture-activated rat hepatic stellate cells. S1P2 expression, determined in S1P mice, was highly increased in hepatic stellate cells of bile duct-ligated livers.